This site is intended for Healthcare Professionals only.

RPS urges social media to ban content promoting or selling DNP

Date:

Share post:

The Royal Pharmaceutical Society (RPS) has called for a ‘firm commitment’ to prosecuting those making profits through the sale of DNP (2,4-Dinitrophenol).

It has also urged the social media companies to ‘remove content promoting or selling DNP to further reduce harm’.

Legislation to regulate DNP will come into effect on 1 October 2023. On Monday (23 January) it was announced that DNP will be included in the 1972 Poisons Act.

President of RPS Professor Claire Anderson said: “DNP is unfit for human consumption and its main use is in the manufacture of explosives and pesticides. It is sold by unscrupulous dealers to vulnerable individuals wanting to lose weight but has a dangerous effect on the metabolism and has led to 32 deaths since 2007 in those taking it as a ‘diet drug’.

“Including DNP in the Poisons Act is a positive move as it will restrict its availability, but what’s really needed is an outright ban to reduce the risk to the public. Australia has already classified DNP as a substance of such a danger to health as to warrant prohibition of sale and we’d like the UK to follow suit.

“We are concerned that DNP is still in circulation and want to see a firm commitment to prosecuting those who make profits from it. We also call on social media companies to remove content promoting or selling DNP to further reduce harm.”

 

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

National Insurance hike: Supporting GPs but not pharmacies an ‘insult,’ says Paul Rees

Pharmacies should be included in the support offered to other NHS services in light of the rise in employer...

GP practices demand protection against National Insurance hike

The Chair of the RCGP stated that the additional financial burden caused by the National Insurance hike will...

Pharmacies invited to apply for COVID-19 vaccination service

The deadline to for submitting response documents for delivering the COVID-19 vaccination service is 19 November NHS England has...

UK approves CStone’s Sugemalimab for non-small cell lung cancer treatment

Patients treated with sugemalimab lived on average 9.0 months without disease progression, compared to 4.9 months in the...